Administration of systemic oncolytic reovirus to patients with melanoma
Certain viruses can both kill cancer cells directly and use a patient’s own immune system to fight their cancer. This project is investigating the use of a one of these viruses (reovirus) in patients with advanced melanoma. The virus will be given to patients before surgical treatment, and the cancerous tissue biopsies will be examined to see what effects the treatment has had on the cancer and the immune system.
- Principle investigator: Dr Christy Ralph
- Leeds Institute of Cancer and Pathology
- Award amount: £215,292
- September 2014 – September 2017
BRAVO: High grade Bladder cancer: A randomised controlled trial of Radical Cystectomy against intra-vesical immunotherapy – A feasibility study
Yorkshire has the worst bladder cancer outcomes in the UK. To try and address this inequality, Professor James Catto and team are undertaking a clinical trial comparing the two main treatment methods for aggressive bladder cancer. This will allow bladder cancer patients to make the best informed choices about their treatment options, improving their quality of life. This project also aims to foster connections between bladder surgeons across Yorkshire, promoting the best standards of care.
- Principle investigator: Professor James Catto
- University of Sheffield
- Award amount: £378,263
- October 2015 – September 2018
The Yorkshire Cancer Research Centre for Early Phase Clinical Trials
The YCR Centre for Early Phase Clinical Trials is a Yorkshire-wide network, created to support the development of new trials for cancer patients in Yorkshire. It aims to give more Yorkshire-based patients the opportunity to participate in innovative early clinical trials, enabling earlier access to novel and more targeted treatments.
These trials are initial studies of potential new therapeutic strategies, before further testing in larger trials. This infrastructure will make Yorkshire a more attractive place for industry to invest in development of new cancer treatments and ensure our cancer research remains internationally competitive.
The Centre is currently supporting 9 early phase clinical trials and research projects.
- Principle investigators: Professor Julia Brown, Dr Sarah Brown, Professor Robert Coleman, Dr Fiona Collinson, Professor Michael Lind, Professor Norman Maitland, Professor David Sebag-Montefiore, Professor Chris Twelves and Professor Penella Woll
- University of Leeds
- Award amount: £724,339
- June 2013 – June 2019
A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases (The EMT2 study)
In bowel cancer patients where the cancer has spread to the liver, surgery to remove the liver cancer is often the best treatment option. Unfortunately, the cancer will recur in a large proportion of these patients, leading to increased mortality. A small-scale trial has shown that taking omega-3 fish oil supplements before and after surgery may have a positive impact on patient survival. A team led by Professor Mark Hull aims to scale up this research to see if omega-3 fish oil can help prevent cancer coming back after surgery.
- Principle investigator: Professor Mark Hull
- University of Leeds
- Award amount: £1,496,870
- October 2015 – March 2021
- Last updated: 24/06/2016
- View more in: Research